Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.

ABSTRACT:

Importance

Five medications have been approved for the management of obesity, but data on comparative effectiveness are limited.

Objective

To compare weight loss and adverse events among drug treatments for obesity using a systematic review and network meta-analysis.

Data sources

MEDLINE, EMBASE, Web of Science, Scopus, and Cochrane Central from inception to March 23, 2016; clinical trial registries.

Study selection

Randomized clinical trials conducted among overweight and obese adults treated with US Food and Drug Administration-approved long-term weight loss agents (orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, or liraglutide) for at least 1 year compared with another active agent or placebo.

Data extraction and synthesis

Two inve

SUBMITTER: Khera R 

PROVIDER: S-EPMC5617638 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature